Drug
Axitinib clinical trials
Also written AG-013736 and Inlyta.
- studies test it
- 159
- open now
- 25
- in phase 3
- 13
- first study started
- 2002
Keep track of what changes. Save the Axitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Inlyta
- 42
Studies by the year they started
159 studies that test it; most in 2011 (13)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 6 |
| 2009 | 9 |
| 2010 | 6 |
| 2011 | 13 |
| 2012 | 13 |
| 2013 | 3 |
| 2014 | 7 |
| 2015 | 5 |
| 2016 | 11 |
| 2017 | 6 |
| 2018 | 5 |
| 2019 | 6 |
| 2020 | 11 |
| 2021 | 8 |
| 2022 | 7 |
| 2023 | 9 |
| 2024 | 7 |
| 2025 | 4 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 46
- Phase 2
- 112
- Phase 3
- 13
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 54 · Other 105
Pfizer (37) · M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Ocular Therapeutix, Inc. (3) · Memorial Sloan Kettering Cancer Center (3) · Chinese University of Hong Kong (3) · The Netherlands Cancer Institute (3)
Often tested with
Tested in the same studies.
Toripalimab (14) · Avelumab (14) · Pembrolizumab (11) · Crizotinib (6) · Nivolumab (5) · Palbociclib (5) · Sunitinib (5) · Talazoparib (4)
Studies
Open first, then newest update. How each study uses Axitinib is read from its arms, and is right about nine times in ten.
Testing it · 159
- Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom TrialRecruitingPhase 1M.D. Anderson Cancer CenterNCT04693468Written as Axitinib
- MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary CarcinomasNot yet recruitingPhase 2Fudan UniversityNCT07816770Written as Axitinib
- TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell CarcinomaNot yet recruitingPhase 2Fudan UniversityNCT07776717Written as Axitinib
- A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell CarcinomaRecruitingPhase 2Stephanie BergNCT07123090Written as Axitinib
- SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell CarcinomaRecruitingPhase 2Hebei Medical University Fourth HospitalNCT07744932Written as axitinib plus toripalimab
- A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal MelanomaEnrolling by invitationPhase 1Peking University Cancer Hospital & InstituteNCT06424626Written as AK104+Axitinib
- Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 StudyRecruitingPhase 3Ocular Therapeutix, Inc.NCT07516132Written as OTX-TKI
- Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor ThrombusRecruitingPhase 2University of Colorado, DenverNCT05969496Written as Axitinib
- Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell CarcinomaNot yet recruitingNot applicableQilu Hospital of Shandong UniversityNCT07500831Written as Axitinib
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606Written as Axitinib
- Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell CarcinomaRecruitingPhase 3ZHOU FANGJIANNCT05738694Written as Axitinib plus Toripalimab
- An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell CarcinomaRecruitingPhase 2Yonsei UniversityNCT07469683Written as SLC-3010 + Axitinib
- Axitinib and Nivolumab for the Treatment of Mucosal MelanomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05384496Written as axitinib
- Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCCRecruitingPhase 2Tianjin Medical University Second HospitalNCT07172386Written as Toripalimab and axitinib
- Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaNot yet recruitingPhase 2Peking Union Medical College HospitalNCT07159191Written as Envafolimab Injection, Axitinib Tablets
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingPhase 2Ulrik LassenNCT04341181Written as Axitinib
- SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCCRecruitingPhase 2Peking University First HospitalNCT06889649Written as Axitinib (VEGF-TKI)
- CARE1 Pragmatic Clinical TrialRecruitingPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT06364631Written as Axitinib
- Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct CarcinomaRecruitingPhase 2Peking University Cancer Hospital & InstituteNCT06211114Written as Axitinib
- Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell CarcinomaNot yet recruitingPhase 2RenJi HospitalNCT06279403Written as Axitinib
See all 159 studies that test Axitinib →
Given in every arm · 16 — Axitinib is usual care beside what is tested
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialRecruitingPhase 2NRG OncologyNCT05327686Written as Axitinib
- Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerRecruitingPhase 1/2PfizerNCT07227415Written as Axitinib
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerRecruitingPhase 3SWOG Cancer Research NetworkNCT07383441Written as Axitinib
- PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCCNot yet recruitingPhase 1/2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07630363Written as Axitinib
- A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal CancerRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT06962787Written as Axitinib
- Axitinib +/- Pembrolizumab in First Line Treatment of mPRCCRecruitingPhase 2Centre Leon BerardNCT05096390Written as Axitinib Oral Tablet [Inlyta]
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingActive, not recruitingPhase 3PfizerNCT05059522Written as Axitinib
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomaActive, not recruitingPhase 2Hoffmann-La RocheNCT05805501Written as Axitinib
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)CompletedPhase 1Merck Sharp & Dohme LLCNCT05017012Written as Axitinib
- Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedPhase 1PfizerNCT04458259Written as Axitinib
- Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney CancerActive, not recruitingPhase 2University of Southern CaliforniaNCT03092856Written as Axitinib
- Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)TerminatedPhase 1/2PfizerNCT04585815Written as Axitinib
- Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid TumorsWithdrawnPhase 1National Cancer Institute (NCI)NCT06161558Written as Axitinib
- CLN-0046: Treatment of AMD Subjects With OTX-TKICompletedPhase 1Ocular Therapeutix, Inc.NCT03630315Written as OTX-TKI
- A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has SpreadCompletedPhase 1Bristol-Myers SquibbNCT04540705Written as Axitinib
- PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell CarcinomaTerminatedPhase 2PfizerNCT01441414Written as Axitinib (AG-013736)
As the comparator · 4 — what is tested is compared with Axitinib
- Combination of Toripalimab and JS004 Therapy for ccRCCRecruitingPhase 2Fudan UniversityNCT06690697Written as Axitinib
- Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)CompletedPhase 2/3HutchmedNCT05522231Written as axitinib / everolimus
- A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell CarcinomaCompletedPhase 2Astellas Pharma Global Development, Inc.NCT02639182Written as Axitinib
- Phase II Study in the Treatment of Patients With Advanced Mucinous MelanomaStatus unknownPhase 2Peking University Cancer Hospital & InstituteNCT03941795Written as Axitinib 1 MG [Inlyta]
Codes
What other systems call Axitinib · ClinicalTrials.gg INT006807
- MeSH (NLM) D000077784AxitinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) C9LVQ0YUXGAXITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1242999Confirmed FDA, Wikidata
- Wikidata Q4830631axitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C38718AxitinibOne source FDA
- DrugBank DB06626One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077784 | Axitinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | C9LVQ0YUXG | AXITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1242999 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4830631 | axitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C38718 | Axitinib | One source FDA |
| DrugBank | DB06626 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.